(A) T47D and (B) MDA-MB-231 cell were incubated for 24 h in the absence (Con) or presence (TBCA) of 25 M TBCA. patients with grade 1 or 2 tumors, as well as among those patients receiving hormonal therapy. Biochemical inhibition of CK2 activity results in increased ER-transactivation as well as increased expression among ER (+) and ER () breast cancer cell lines. These findings suggest that CK2 may contribute to estrogen-independent cell proliferation and breast tumor SMOC1 progression, and may potentially serve as a biomarker and pharmacological target in breast cancer. Keywords: CK2, estrogen receptor (ER), relapse free survival, breast cancer == 1 . Introduction == Despite recent advances in detection and therapeutic intervention, breast cancer remains the second most common cause of cancer-related death among American women. Most breast cancers are ER (+), making those patients eligible for treatment with hormonal therapy. However , as many as 60% of women progress to become resistant to hormonal therapies [1]. Furthermore, a minority of patients have ER () disease, and are inherently resistant to hormonal therapies. In either case, patients are relegated to cytotoxic chemotherapy and are subject to the associated severe side effects. As such, it is imperative to determine the mechanisms by which patients develop estrogen resistance, as well as to develop more targeted therapies to reverse endocrine resistance in breast cancer. Protein kinase CK2 is a pleiotropic, heterotetrameric serine kinase consisting of two regulatory subunits, and 2 catalytic subunits, ( and ) [2, 3]. CK2 activity has been shown to be significantly elevated in cancerous versus normal tissues, including patient-matched colorectal and breast tissues [4]. As such, several studies have been YHO-13177 initiated to identify drugs which selectively and potently inhibit CK2 activity [5]. Two such agents CIGB-300 (cyclic peptide) and silmitasertib (CX-4945) are currently being targeted in two clinical trials for the treatment of cervical cancer (CIGB-300), or multiple myeloma, cholangiosarcoma, and advanced solid tumors including breast (CX-4945) [6, 7]. More recently, a large scalein vitroscreening of the NIH/NCI chemical Diversity Set Library has identified 1, 3-Dichloro-6-[(E)-((4-methoxyphenyl)imino)methyl] dibenzo(b, d) furan-2, 7-diol as a novel potent, selective and cell permeable inhibitor of protein kinase CK2 [8]. Additionally , molecular modeling studies have led to the development of a series of dihydroxyindeno [1, 2-b]indole derivatives which inhibit CK2 kinase activity at nanomloar concentrations [9]. These studies highlight the potential for development of pharmacological inhibitors of CK2 for cancer treatment. A recent study by Ortegaet al., showed that CK2 mRNA is overexpressed in cancerousversusnormal tissue of the breast, lung, ovarian, prostate, renal, and colon, as well as others [10]. Another recent study has demonstrated that CK2 is statistically overexpressed in basal breast cancer as compared to either normal breast epithelium or the well-differentiated luminal a subtype [11]. In tumor microarray studies, CK2 was identified as a part of a 9-marker gene expression signature associated with increased metastatic risk among breast cancer patients [6]. Studies have shown that transgenic overexpression of CK2 in the rat mammary gland results in tumor development in 30% of animals [12]. Additionally , it was shown that 20 out of 21 independent gene expression microarrays tested, CK2 was overexpressed in breast carcinoma versus normal breast epithelium [10]. Together, these YHO-13177 studies suggest that overexpression of CK2 may be causative in human breast oncogenesis. Interestingly, in vitrostudies have shown that DMAT, YHO-13177 the selective inhibitor of CK2, induces apoptosis in tamoxifen-resistant, but not wild-type MCF-7 breast cancer cell lines [13]. Our own previously published studies have shown that CK2 can phosphorylate human ER at S282 and S559 bothin vitroandin vivo, and that mutation of CK2 sites results in a moderate but significant increase in ER transcriptional activity [14]. Where most findings have suggested that CK2 is a negative prognostic indicator in breast cancer, no studies to date have examined the intersection between ER and CK2 signaling. Here, we mined publically available microarray repositories to ascertain the significance of CK2 expression to relapse free survival (RFS) based on ER status, histological grade, and hormonal therapy. We investigated the impact of CK2 inhibition on ER-dependent transactivationin vitro, and subsequently of ER expression. Our findings suggest that CK2 is a key signaling component in the progression of ER (+) breast cancer to a more aggressive phenotype. YHO-13177 == 2 . Materials and Methods == == 2 . 1 . Kaplan Meier Survival Analysis == The application of KM plot has been described in detail previously [15, 16]..